[HTML][HTML] Digital biomarker–based studies: scoping review of systematic reviews

H Motahari-Nezhad, M Fgaier… - JMIR mHealth and …, 2022 - mhealth.jmir.org
Background Sensors and digital devices have revolutionized the measurement, collection,
and storage of behavioral and physiological data, leading to the new term digital …

Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: a systematic review and network meta-analysis …

J Bao, R Kan, J Chen, H Xuan, C Wang, D Li… - Pharmacological …, 2021 - Elsevier
Pharmacotherapies, including angiotensin-converting enzyme inhibitors (ACEIs),
angiotensin receptor II blockers (ARBs), β-blockers (BBs), mineralocorticoid receptor …

Comparative efficacy and safety of different catheter ablation strategies for persistent atrial fibrillation: a network meta-analysis of randomized clinical trials

A Saglietto, A Ballatore, F Gaita… - … Journal-Quality of …, 2022 - academic.oup.com
Aims Whereas pulmonary vein isolation (PVI) is the universally agreed target in catheter
ablation of paroxysmal atrial fibrillation (AF), an ideal ablation set in persistent AF remains …

Treating symptoms and reversing remodelling: clinical and echocardiographic 1‐year outcomes with percutaneous mitral annuloplasty for mild to moderate secondary …

KK Witte, DM Kaye, J Lipiecki… - European Journal of …, 2021 - Wiley Online Library
Aims To determine the effects of percutaneous mitral annuloplasty on symptoms, walk
distance and left ventricular (LV) structure and function in patients with mild or moderate …

Ten years of subcutaneous defibrillator therapy: Consolidated clinical evidence and future perspectives

S Magnani, H Ali, R Cappato - Journal of Cardiovascular …, 2024 - Wiley Online Library
The subcutaneous implantable cardioverter defibrillator (S‐ICD) was developed as an
alternative to the traditional transvenous implantable cardioverter defibrillator (TV‐ICD) …

Adjuvant testosterone therapy in chronic heart failure (ATTIC): a randomised open-label trial

M Dhar, K Mittal, A Parchani, M Sharma, Y Bahurupi… - BMJ open, 2022 - bmjopen.bmj.com
Introduction Heart failure is a major contributor to morbidity and mortality in the geriatric
population, with no promising therapy currently available with considerable benefit …

[HTML][HTML] Short-term effect of stock volatility and cardiovascular mortality: a systematic review and meta-analysis

H Lian, X Ding, H Zhang, X Wang - Annals of Translational …, 2020 - ncbi.nlm.nih.gov
Background Cardiovascular disease (CVD) and stroke are leading causes of death. It has
several risk factors, including stress and pressure. Stock volatility can cause acute stress for …

[HTML][HTML] Сердечная ресинхронизирующая терапия у больных с хронической сердечной недостаточностью: взгляд терапевта, кардиолога

ЕВ Резник, СЮ Солтис, ДВ Устюжанин… - …, 2019 - cyberleninka.ru
В связи с успехами кардиологии и увеличением продолжительности жизни населения
распространенность хронической сердечной недостаточности неуклонно растет. Это …

Methodological challenges in the evidence synthesis of health outcomes of digital health technologies

H Motahari Nezhad - 2023 - phd.lib.uni-corvinus.hu
Medical devices and pharmaceuticals are worlds apart, but healthcare would be impossible
without them. Digital biomarkers are the subject of this thesis defined as objective …

[HTML][HTML] Avanços no Tratamento de Insuficiência Cardíaca: Perspectivas e Terapêuticas Emergentes

AAZ Junior, LWB Caldas, JC Colnago… - Brazilian Journal of …, 2024 - bjihs.emnuvens.com.br
O tratamento por meio de terapias inovadoras para a deficiência de hormônio do
crescimento representa uma abordagem avançada para lidar com essa condição endócrina …